The theoretical population-level impact of a prophylactic human papilloma virus vaccine

Epidemiology

Volumn 13, Issue 6, 2002, Pages 631-639

  Hughes, James P ^a   Garnett, Geoff P ^b   Koutsky, Laura ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Cervical; Human; Model; Papillomavirus; Theoretical; Vaccine

Indexed keywords

WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE; VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFECTION PREVENTION; MALE; MATHEMATICAL MODEL; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; WART VIRUS; PAPILLOMA VIRUS; SEX DIFFERENCE; THEORETICAL MODEL; UTERINE CERVIX TUMOR;

FEMALE; HUMANS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEX FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 0036832108     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-200211000-00006     Document Type: Article

References (17)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1980;41: 184-197.
2. Alexander LL, Cates JR, Herndon N, Ratcliffe JF. Sexually Transmitted Diseases in America. Available at: http://www.ashastd.org. Accessed 2 May 2002. American Social Health Association, Research Triangle Park, NC.
3. Bosch FX, Rohan T, Schneider A, et al. Papillomavirus research update: highlights of the Barcelona HPV 2000 international papillomavirus conference. J Clin Pathol 2001;54:163-175.
4. Anderson RM, May RM. Directly transmitted infectious diseases-control by vaccination. Science 1982;215:1053-1060.
5. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for D.S. children. JAMA 1994;271:375-381.
6. Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: A mathematical model for evaluating costs and effectiveness of immunization programmes. Epioemiol Infect 1996;116:71-89.
7. McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc Royal Soc Lond B 1993;253:9-13.
8. Garnett GP. The influence of behavioral heterogeneity on the population level effect of potential prophylactic type 1 human immunodeficiency virus vaccines. J Royal Statist Soc A 1998;161: 209-225.
9. Koopman JS, Little RJ. Assessing HIV vaccine effects. Am J Epidemiol 1995;142:1113-1120.
10. Meyers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151:1158-1171.
11. Sherlaw-Johnson C, Gallivan S, Jenkins D. Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ 1999;318:356-361.
12. Garnett GP, Waddell H. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 2000;19:101-111.
13. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press, 1991.
14. Garnett GP, Anderson RM. Contact tracing and the estimation of sexual mixing patterns: the epidemiology of gonoccal infections. Sex Transm Dis 1993;20:181-191.
15. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-1102.
16. Silins I, Wang Z, Avall-Lundqvist E, et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999;80: 2931-2936.
17. Luostarinen T, Geijersstam V, Bjorge T, et al. No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. Int J Cancer 1999;80:818-822.